Clinical Trials
25 trialsTAPUR
American Society of Clinical Oncology
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Eastern Cooperative Oncology Group
Pediatric Long-Term Follow-up and Rollover Study
Novartis
MegaMOST
Centre Leon Berard
Dabrafenib and/or Trametinib Rollover Study
Novartis
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
City of Hope Medical Center
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
NeoLATC
Fujian Medical University
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
Special Drug Use-results Surveillance of Tafinlar/Mekinist
Novartis
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Fudan University
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Ann & Robert H Lurie Children's Hospital of Chicago
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
MATRIX-Rare
Oslo University Hospital
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
NETCAM
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
FINPROVE
Helsinki University Central Hospital
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Saint Petersburg State University, Russia
Swecranio
Skane University Hospital
DRUP
The Netherlands Cancer Institute
NEO-ATACT
Leiden University Medical Center
MEMBRAINS
Herlev Hospital